medicine

Developed by UCLA’s Dr. Leonard Rome and Dr. Steven Dubinett, the treatment combines an immunotherapy agent with a drug delivery nanotechnology using nanoparticles called vaults.

A researcher at UCLA’s Jonsson Comprehensive Cancer Center helped develop the combination drug therapy that also lowers the risk of secondary cancers.

Souped-up antibiotics effectively attack persister cells that are responsible for making bacteria resistant to new drugs.

‘Souped-up’ antibiotics could give doctors an advantage over bacteria that have develop immunity to medicines.

“In short, if you think a pill is going to work, it probably will,” says UCLA professor who led the study, which evaluated patients who received therapy and either real medication or a sugar pill.

High doses appear not to offer the same benefit, but the lower dosage may be a safe, low-cost way to help people with epilepsy, UCLA study suggests.

Approval of Keytruda signals a paradigm shift in the way advanced melanoma is treated. The drug was tested on more than 600 patients in the U.S., Europe and Australia.

UCLA-led research finds that a variant of an existing vaccine offers stronger protection against both diseases and with the addition of a particular protein, further boosts protection against leprosy.

Through shared decision-making, patients and their physicians become true collaborators in determining the best course of care.

Across California, there is a dearth of Spanish-speaking, culturally adept primary care physicians. The UCLA International Medical Graduate program is addressing this gap by training Hispanic international medical graduates from medical schools recognized by the Medical Board of California.

The multi-site clinical trial, which aims to identify and implement effective, evidence-based strategies to combat falls, will be co-led by Dr. David Reuben, chief of the UCLA Division of Geriatrics.

With millions in the West now utilizing traditional Chinese medicine, the need for accurate medical translations is more crucial than ever, the authors of a new UCLA paper say.

The campus is one of six U.S. institutions chosen by the NIH to join the agency's efforts to tackle the most difficult-to-solve medical cases and develop ways to diagnose rare genetic disorders.

A working group that includes UCLA's Susan D. Cochran says the removal of these disorders from the organization's classification system will make getting health care easier for gay individuals.

With online feedback, surgeons improved their technique, had shorter completion times and earned better scores technical efficiency, accuracy and economy of motion.

Their Center for Duchenne Muscular Dystrophy is leading a very personal fight to find treatments and extend lives — including that of their son.

The combination of the female hormone estriol with a commonly used MS drug appears to lower the relapse rate by nearly 50 percent.